Provided by Tiger Trade Technology Pte. Ltd.

ANI Pharmaceuticals

75.35
-1.9700-2.55%
Pre-market: 75.31-0.0400-0.05%04:23 EDT
Volume:379.16K
Turnover:28.69M
Market Cap:1.73B
PE:16.60
High:77.81
Open:77.33
Low:74.81
Close:77.32
52wk High:99.50
52wk Low:70.15
Shares:22.97M
Float Shares:20.28M
Volume Ratio:1.41
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.54
EPS(LYR):3.32
ROE:20.46%
ROA:5.45%
PB:2.90
PE(LYR):22.70

Loading ...

ANI Pharmaceuticals Announces Publication of New Day Clinical Trial Results in Ophthalmology

THOMSON REUTERS
·
Apr 07

ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology

GlobeNewswire
·
Apr 07

ANI Pharmaceuticals (ANIP) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Mar 25

Barclays Keeps Their Buy Rating on ANI Pharmaceuticals (ANIP)

TIPRANKS
·
Mar 19

Is ANI Pharmaceuticals (ANIP) Pullback Hiding A Contradiction In Its Valuation Story

Simply Wall St.
·
Mar 18

ANI Pharmaceuticals Head of Rare Disease Christopher Mutz Disposes of Common Shares

Reuters
·
Mar 14

ANI Pharmaceuticals Sr. VP, General Counsel and Secretary Meredith Cook Disposes of Common Shares

Reuters
·
Mar 14

ANI Pharmaceuticals Head of Rare Disease Christopher Mutz Disposes of Common Shares

Reuters
·
Mar 05

ANI Pharmaceuticals SVP, Generics Ori Gutwerg Disposes of Common Shares

Reuters
·
Mar 05

ANI Pharmaceuticals Director Patrick D. Walsh Disposes of Common Shares

Reuters
·
Mar 04

ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors

TIPRANKS
·
Mar 03

ANI Pharmaceuticals Publishes Corporate Presentation on Rare Disease Growth Strategy and 2026 Revenue Outlook

Reuters
·
Mar 03

ANI Pharmaceuticals Signals Strong Growth in 2025 Call

TIPRANKS
·
Mar 02

Does Record 2025 Profitability and Reaffirmed 2026 Outlook Change The Bull Case For ANI Pharmaceuticals (ANIP)?

Simply Wall St.
·
Mar 01

H.C. Wainwright Keeps Their Buy Rating on ANI Pharmaceuticals (ANIP)

TIPRANKS
·
Feb 28

Stock Track | ANI Pharmaceuticals Plummets 5.17% Intraday Despite Strong Earnings as Health Care Sector Weakens

Stock Track
·
Feb 28

ANI Pharma Q4 profit beats on rare disease, generics growth; reaffims forecast

Reuters
·
Feb 27

ANI Pharmaceuticals Q4 Adj. EPS $2.33 Beats $2.00 Estimate, Sales $247.060M Beat $231.534M Estimate

Benzinga Earnings
·
Feb 27

ANI Pharmaceuticals reports Q4 adjusted EPS $2.33, consensus $1.98

TIPRANKS
·
Feb 27

ANI Pharmaceuticals sees FY26 adjusted EPS $8.83-$9.34, consensus $8.64

TIPRANKS
·
Feb 27